Manufacturing

Articles

The companies will collaborate on the production of a novel anti-SARS-CoV-2 immunoadhesin in iBio’s FastPharming manufacturing system.

iBio and Planet Biotechnology Partner to Develop COVID-19 Therapeutic

In the study, GigaGen presents a novel technology for producing a new class of drug, recombinant hyperimmunes, that may potentially generate new COVID-19 therapies.

GigaGen Highlights Research Describing New Class of Drugs for Potential COVID-19 Therapy

The technology enables the rapid production of large numbers of recombinant antibodies at 80-mL scale.

Absolute Antibody Launches New, High-Throughput Recombinant Antibody Production Service

The company presented data on its G2 glycosylation studies at the 15th European Conference on Fungal Genetics in Rome on Feb. 19, 2020.

Dyadic Achieves G2 Human-Like Glycosylation Milestone

GE Healthcare Life Sciences’ KUBio box is an integrated, flexible biomanufacturing environment for viral vector-based gene therapies.

GE Healthcare Launches Viral Vector-Based Gene Therapy Manufacturing

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

The evolution of cell-culture technology is driving the need for improvements in modeling solutions.

Cell-Culture Advances Test Bioreactor Performance Models

Large biopharmas, emerging biotechs, and CMOs are looking for novel ways to improve the productivity of biologics in a rapidly evolving biotherapeutics market.

The Search for Bioprocess Productivity Improvement

Pharmaceutical Technology and BioPharm International will present a Keynote Session on Meeting Bioprocessing Manufacturing Capacity Demands on Wednesday, April 3, 2019, during INTERPHEX 2019 at the Javits Center in New York City.

Biologic Drug Manufacturing Capacity on the Agenda for INTERPHEX 2019 Keynote Series

G-CON will provide a complete cleanroom infrastructure for GE Healthcare’s cell therapy and viral vector production platforms that will simplify early-stage manufacturing efforts.

G-CON Manufacturing and GE Healthcare Collaborate to Advance Early-Stage Cell Therapy and Viral Vector Manufacturing

The agreement gives Sanofi access to Biomunex’s proprietary bi- and multi-specific-antibody-generating platform.

Manufacturing, Expression Systems